Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering.
The major event initiating atherosclerosis is hypercholesterolemia-induced disruption of vascular endothelium integrity. In settings of endothelial damage, endothelial progenitor cells (EPCs) are mobilized from bone marrow into circulation and home to sites of vascular injury where they aid endothelial regeneration. Given the beneficial effects of EPCs in vascular repair, we hypothesized that these cells play a pivotal role in atherosclerosis regression. We tested our hypothesis in the atherosclerosis-prone mouse model in which hypercholesterolemia, one of the main factors affecting EPC homeostasis, is reversible (Reversa mice). In these mice, normalization of plasma lipids decreased atherosclerotic burden; however, plaque regression was incomplete. To explore whether endothelial progenitors contribute to atherosclerosis regression, bone marrow EPCs from a transgenic strain expressing green fluorescent protein (GFP) under the control of endothelial cell-specific Tie2 promoter (Tie2-GFP(+)) were isolated. These cells were then adoptively transferred into atheroregressing Reversa recipients where they augmented plaque regression induced by reversal of hypercholesterolemia. Advanced plaque regression correlated with engraftment of Tie2-GFP(+) EPCs into endothelium and resulted in an increase in atheroprotective nitric oxide and improved vascular relaxation. Similarly augmented plaque regression was also detected in regressing Reversa mice treated with the stem cell mobilizer AMD3100 which also mobilizes EPCs to peripheral blood. We conclude that correction of hypercholesterolemia in Reversa mice leads to partial plaque regression that can be augmented by AMD3100 treatment or by adoptive transfer of EPCs. This suggests that direct cell therapy or indirect progenitor cell mobilization therapy may be used in combination with statins to treat atherosclerosis.
Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Longbiao
L
Yao
Janet
J
Heuser-Baker
Oana
O
Herlea-Pana
Ryuji
R
Iida
Qilong
Q
Wang
Ming-Hui
MH
Zou
Jana
J
Barlic-Dicen
D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000473:pathology / Q000628:therapy; D001596:Benzylamines; D001854:Bone Marrow Cells / Q000166:cytology*; D002478:Cells, Cultured; D000080027:Cyclams; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000166:cytology / Q000637:transplantation*; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000628:therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000097:blood; D018384:Oxidative Stress / Q000502:physiology; D058226:Plaque, Atherosclerotic / Q000097:blood / Q000473:pathology / Q000628:therapy*; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology*; D014664:Vasodilation / Q000187:drug effects
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D008055:Lipids; D009569:Nitric Oxide; C088327:plerixafor